1Research and Analysis Team, National Health Insurance Service Ilsan Hospital, Goyang, Korea
2Research Institute of National Health Insurance Service Ilsan Hospital, Goyang, Korea
3Department of Big Data, National Health Insurance Service, Wonju, Korea
4Medical Library, National Health Insurance Service Ilsan Hospital, Goyang, Korea
5Department of Otolaryngology-Head and Neck Surgery, National Health Insurance Service Ilsan Hospital, Goyang, Korea
6Pathology, National Health Insurance Service Ilsan Hospital, Goyang, Korea
7Physical Medicine and Rehabilitation, National Health Insurance Service Ilsan Hospital, Goyang, Korea
8Division of Endocrinology and Metabolism, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea
Copyright © 2020 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTIONS
Conception or design: S.Y.C., D.W.K., S.O.S.
Acquisition, analysis, or interpretation of data: S.Y.C., D.W.K., S.A.L., S.J.L., J.H.C., Y.J.C., S.W.K., S.O.S.
Drafting the work or revising: S.Y.C., S.O.S.
Final approval of the manuscript: S.Y.C., S.O.S.
Values are presented as number (%).
COVID-19, coronavirus disease 2019; DM, diabetes mellitus; OHA, oral hypoglycemic agent; NA, not applicable; aGI, alpha-glucosidase inhibitor; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1, glucagon-like peptide-1; SU, sulfonylurea; SGLT2i, sodium-glucose cotransporter 2 inhibitor; TZD, thiazolidinedione.